Three million people in this country have chronic wounds and this number is increasing by 6% per year mainly due to the wounds in the increasing number of type 2 diabetics. The current wound care costs are staggering, reaching $50 billion per year. In our research, innovative and practical methodology to treat wounds is used where individual wounds are treated in sealed transparent chambers. With the use of this model, the wound microenvironment can readily be modified in a specific fashion like a tissue culture in vivo. The wound chamber provides very reproducible experimental conditions and has clinical benefits. A new porcine diabetic wound model using the wound chamber has demonstrated delayed healing compared to healthy pigs. Preliminary data has also demonstrated decreased expression of IGF-1, and a greater response to fibroblast and keratinocyte transplantation in diabetic pigs compared to healthy controls. We hypothesize that transplantation of transgenic keratinocytes and fibroblasts expressing certain growth factors under the control of a tetracycline-regulated gene switch will restore healing in diabetic porcine skin wounds. This research program includes two new methodologies: 1) a streptozotocin-induced diabetic wound model and 2) regulatable delivery of proteins by using autologous keratinocyte and fibroblast cell lines transfected with tetracycline operator/represser controlled genes. Because gene transfer offers targeted and persistent delivery of therapeutic polypeptides, a single genetic intervention might be sufficient to promote wound repair adequately. Furthermore, the use of the tetracycline operator/represser system allows timing of onset and precise titration of the delivered proteins as well as sequential expression of these proteins, which could maximize the biological effect of the growth factors delivered. These methodologies will help us understand and treat diabetic wounds. This constitutes a safe and practical system for in vivo gene delivery to skin wounds, offering therapeutic potential for other skin diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
2R01GM051449-09A1
Application #
6874591
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Ikeda, Richard A
Project Start
1995-08-01
Project End
2009-02-28
Budget Start
2005-03-03
Budget End
2006-02-28
Support Year
9
Fiscal Year
2005
Total Cost
$391,322
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Hackl, Florian; Bergmann, Juri; Granter, Scott R et al. (2012) Epidermal regeneration by micrograft transplantation with immediate 100-fold expansion. Plast Reconstr Surg 129:443e-452e
Koyama, Taro; Hackl, Florian; Aflaki, Pejman et al. (2011) A new technique of ex vivo gene delivery of VEGF to wounds using genetically modified skin particles promotes wound angiogenesis. J Am Coll Surg 212:340-8
Zuhaili, Baraa; Aflaki, Pejman; Koyama, Taro et al. (2010) Meshed skin grafts placed upside down can take if desiccation is prevented. Plast Reconstr Surg 125:855-65
Lu, Zheming; Brans, Richard; Akhrameyeva, Natali V et al. (2009) High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection. J Invest Dermatol 129:1174-84
Brans, Richard; Eriksson, Elof; Yao, Feng (2008) Immunization with a dominant-negative recombinant HSV type 1 protects against HSV-1 skin disease in guinea pigs. J Invest Dermatol 128:2825-32
Hirsch, Tobias; Spielmann, Malte; Velander, Patrik et al. (2008) Insulin-like growth factor-1 gene therapy and cell transplantation in diabetic wounds. J Gene Med 10:1247-52
Vranckx, Jan Jeroen; Hoeller, Daniela; Velander, Patrik E M et al. (2007) Cell suspension cultures of allogenic keratinocytes are efficient carriers for ex vivo gene transfer and accelerate the healing of full-thickness skin wounds by overexpression of human epidermal growth factor. Wound Repair Regen 15:657-64
Yao, Feng; Pomahac, Bohdan; Visovatti, Scott et al. (2007) Systemic and localized reversible regulation of transgene expression by tetracycline with tetR-mediated transcription repression switch. J Surg Res 138:267-74
Yao, Feng; Theopold, Christoph; Hoeller, Daniela et al. (2006) Highly efficient regulation of gene expression by tetracycline in a replication-defective herpes simplex viral vector. Mol Ther 13:1133-41
Augustinova, Hanka; Hoeller, Daniela; Yao, Feng (2004) The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice. J Virol 78:5756-65

Showing the most recent 10 out of 19 publications